Loading organizations...
Heritas Venture Fund, a Singapore-based fund management firm, invests in private equity, venture capital, and fund-of-funds across healthcare, education, environment, and technology sectors globally. The firm manages assets exceeding $250 million, including the $15 million Heritas Venture Fund I launched in 2017 and the $30 million Heritas Venture Fund II, which targeted a 2021 launch. It also plans a $150 million Heritas Growth Fund III and partners with SEEDS Capital, co-investing with entities like the Michael and Susan Dell Foundation. Its portfolio features companies such as Holmusk, Hummingbird Bioscience, Alchemy Foodtech, and SilverConnect. The firm operates with fewer than 25 employees. Established in 1997 as the investment arm of IMC Group, Heritas Capital obtained its independent fund management license in 2013.
Heritas Venture Fund has 2 tracked investments across 1 company. The latest tracked deal is $25.0M Other Equity in CXA Group in March 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 12, 2019 | CXA Group | $25.0M Other Equity | — | B Capital Group, Rosaline KOO, EDBI, HSBC, Humanica, MDI Ventures, Muang Thai Fuchsia Ventures, Singtel Innov8, Sumitomo Corporation Equity Asia |
| Mar 1, 2019 | CXA Group | $25.0M Series C | — | B Capital Group, Golden Gate Ventures, Pieter Kemps, Shailendra Singh, CXA Group, EDBI, HSBC, Humanica, MDI Ventures, Muang Thai Fuchsia Ventures, Singtel Innov8, Sumitomo Corporation Equity Asia |
